Skip to main content

This site is intended for U.S. Healthcare Professionals.


Frequently Asked Questions

5 Through 11 Years of Age
Dilute Before Use
(Orange Cap)

Pfizer-BioNTech COVID-19 Vaccine, Bivalent
(Original and Omicron BA.4/BA.5)

FDA AUTHORIZED FOR EMERGENCY USE1-5

Emergency uses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 6 months and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)  (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com.

Questions and Answers About Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) for Ages 5 Through 11 Years

For information about the monovalent Pfizer-BioNTech COVID-19 Vaccine, click here.

Go to Section

Approval and Authorization Status

OPEN ALL

CLOSE ALL

Are individuals ages 5 through 11 years eligible to receive Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) under Emergency Use Authorization?

Yes. Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is authorized for emergency use in individuals 5 through 11 years of age and older as a single booster dose administered at least 2 months after either3:

  • completion of primary vaccination with any authorized or approved COVID-19 vaccine, or
  • receipt of the most recent booster dose with any authorized or approved monovalent* COVID-19 vaccine

*Monovalent refers to any authorized or approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2.

Please see Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) EUA Fact Sheet for Vaccination Providers (Booster Dose 5 through 11 years of age), DILUTE BEFORE USE, Orange Cap and refer to the Dosage & Administration section or the Dosing & Preparation page on the website.

How do I tell the difference between the monovalent orange cap Pfizer-BioNTech COVID-19 Vaccine vial label and the orange cap Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) vial label?

Because both the monovalent* Pfizer-BioNTech COVID-19 Vaccine vial label and Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) presentations of 5 through 11 years of age, DILUTE BEFORE USE vaccine vials have orange caps and labels with an orange border, it is important to look closely at the label itself to determine which of the Orange Cap vaccines you intend to administer.2,3

*Pfizer-BioNTech COVID-19 Vaccine is a monovalent vaccine that encodes the spike protein of only the SARS-CoV-2 Wuhan-Hu-1 strain (Original strain).

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) authorized for use in individuals 5 through 11 years of age has an orange cap and label with orange border and includes the following: Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5).

The monovalent Pfizer-BioNTech COVID-19 Vaccine authorized for use in individuals 5 through 11 years of age has an orange cap and label with orange border and includes the following: Pfizer-BioNTech COVID-19 Vaccine.

Please see the Formulation/Presentation Guide for more information.

Access to Vaccine Supply

OPEN ALL

CLOSE ALL

How can I order the vaccines for my practice, office, hospital, or pharmacy?

The US government is overseeing the distribution and coordination at this time. State and local authorities are responsible for the allocation of doses of populations in their jurisdictions. The CDC uses its current centralized distribution contract to fulfill orders for the most COVID-19 vaccine products and associated ancillary suppliers.6

Pfizer is currently coordinating with the US government and distribution partners to develop plans for future purchasing and distribution, with the hope that providers will be able to access the COVID-19 vaccines in a manner similar to how other Pfizer vaccines are currently purchased and received.7

Whom can I call with product questions?

For product questions, please call customer service at 1-877-829-2619.

What is the cost of BioNTech and Pfizer COVID-19 Vaccines?

The federal government has contracted with McKesson for purposes of vaccine distribution, such that no American will be charged for either the COVID-19 vaccine or its distribution.

In the future, Pfizer plans to announce the list price publicly 60 days prior to offering product for commercial sale.7

Diluent

OPEN ALL

CLOSE ALL

Does Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) for individuals ages 5 through 11 years require dilution?

Yes.3 Please see Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.5/BA.5) EUA Fact Sheet for Vaccination Providers (Booster Dose 5 through 11 years of age), DILUTE BEFORE USE, Orange Cap and refer to the DOSAGE AND ADMINISTRATION section, as well as the Dosing & Preparation page on the website for instructions on how to prepare the vaccines.

How many doses does each vial contain?

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), 5 through 11 years of age, DILUTE BEFORE USE, Orange Cap contains 10 doses of 0.2 mL of vaccine. Low dead-volume syringes and/or needles can be used to extract 10 doses from a single vial. If standard syringes and needles are used, there may not be sufficient volume to extract 10 doses from a single vial. Irrespective of the type of syringe and needle3:

  • Each dose must contain 0.2 mL of vaccine
  • If the amount of vaccine remaining in the vial cannot provide a full dose of 0.2 mL, discard the vial and any excess volume
  • Do not pool excess vaccine from multiple vials

Please see Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.5/BA.5) EUA Fact Sheet for Vaccination Providers (Booster Dose 5 through 11 years of age), DILUTE BEFORE USE, Orange Cap and refer to the DOSAGE AND ADMINISTRATION section or the Dosing & Preparation page on the website for instructions on preparation and administration.

Dosing and Administration

OPEN ALL

CLOSE ALL

What is the dosing schedule for Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)?

A single booster dose (0.2 mL) of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) may be administered at least 2 months after completion of primary vaccination or receipt of the most recent booster dose with any authorized or approved monovalent* COVID-19 vaccine.3


*Monovalent refers to any authorized or approved COVID-19 vaccine that contains or encodes the spike protein of only the Original SARS-CoV-2.

Can I give COVID-19 vaccines at the same time as other vaccines?

According to the vaccine Fact Sheets, there is no information on the co-administration of the Pfizer-BioNTech COVID-19 Vaccine or the Pfizer-BioNTech COVID-19 Vaccine, Bivalent with other vaccines.

Also see the CDC's Summary Document for Interim Clinical Considerations for use of COVID-19 Vaccines Currently Authorized in the United States. [By clicking this link, you will be redirected to a website that is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of this site.]

Is Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), DILUTE BEFORE USE (Orange Cap) only available in a multiple dose vial?

Yes.3

How do I prepare a dose?

Preparation of a dose is dependent on the presentation, which can be identified based on the labeling and cap color of the vaccine vial.

For Orange Cap vials, please see Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.5/BA.5) EUA Fact Sheet for Vaccination Providers (Booster Dose 5 through 11 years of age), DILUTE BEFORE USE, Orange Cap DOSAGE AND ADMINISTRATION section for instructions on how to prepare the vaccine.

Storage and Handling

OPEN ALL

CLOSE ALL

How are Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), 5 through 11 years of age, DILUTE BEFORE USE, Orange Cap vials stored?
The vials may arrive frozen at ultra-cold conditions in thermal shipping containers with dry ice. Once received, frozen vials may be immediately transferred to the refrigerator (2 °C to 8 °C [35 °F to 46 °F]), thawed and stored for up to 10 weeks. The 10-week refrigerated expiry date should be recorded on the carton at the time of transfer. A carton of 10 vials may take up to 4 hours to thaw at this temperature.3

Alternatively, frozen vials may be stored in an ultra-low temperature freezer at -90 °C to -60 °C (-130 °F to -76 °F) for up to 18 months from the date of manufacture. Do not store vials at -25 °C to -15 °C (-13 °F to 5 °F). Once vials are thawed, they should not be refrozen.3

Storage options for Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), 5 through 11 years of age, DILUTE BEFORE USE, Orange Cap3:

Storgae-orange-Dilution Storage-purple-Dilution
Regardless of storage condition, Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) should not be used after 18 months from the date of manufacture printed on the vial and cartons.
How do I know when vials expire?

Visit https://lotexpiry.cvdvaccine.com/ for lot expiry information for BioNTech and Pfizer's COVID-19 vaccines.

How long does it take for frozen Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), 5 through 11 years of age, DILUTE BEFORE USE, Orange Cap vials to thaw?

In the refrigerator at 2 °C to 8 °C (35 °F to 46 °F) 3:

  • 10-pack cartons may take up to 4 hours to thaw

Individual vials will take less time. If needed, a frozen vial may be thawed at room temperature (up to 25 °C [77 °F]) for 30 minutes.

Thermal Shipping Container

OPEN ALL

CLOSE ALL

How do I follow up on the status of my product order?

If you are a healthcare professional trying to locate your order of the vaccine and you reside in the United States, you can call customer service at 1-800-666-7248.

Whom do I contact if I have an issue with my shipment?

If you are a healthcare professional having an issue with your shipment of the vaccine and you reside in the United States, you can call customer service at 1-800-666-7248.

How can I return the Medium Thermal Shipping Container and Temperature-Monitoring Device?
For detail on how to return the Medium Thermal Shipping Container, please refer to the included Instructions. For additional assistance on returns, call Controlant at 1-701-540-4039 if in the US.
How can I return the Temperature-Monitoring Device included with the Single-Use Thermal Shipping Container?

After removal of the Temperature-Monitoring Device and Temperature-Monitoring Device Return Kit, the Single-Use Thermal Shipping Container should be disposed of at your facility. For detail on how to dispose of the Single-Use Thermal Shipping Container, please refer to the included Instructions.

What are the weights and dimensions* of the thermal shipping container and vial cartons?
  • External Dimensions of the AeroSafe 47L7: 17.5" x 17.5" x 21.5"8
  • External Dimensions of Softbox Medium ULT: 15.75" x 15.75" x 22.05"8
  • Dimensions of one 10-pack carton: from approximately 3.35" x 1.46" x 1.85" to 3.50" x 1.46" x 1.85"8
  • Dimensions of one 25-pack carton: 3.31" x 3.35" x 1.54"8
  • Weight range for the Medium ULT thermal shipping containers: approximately 64 lb to 80 lb (29 kg to 36 kg)8
  • External Dimensions of the Sonoco Gen 1 Single Use Thermal Shipper: ~17.125" x 16.125" x 19.125"8
  • External Dimensions of the Sonoco Gen 2 Single Use Thermal Shipper: ~17.125" x 16.125" x 19.75"8

*Please note that dimensions can vary depending on the shipping mode or manufacturing site.

Ensuring Authenticity

OPEN ALL

CLOSE ALL

How can I verify if the vaccine product I receive is authentic?
Ensuring the Authenticity of Pfizer-BioNTech COVID-19 Vaccine; Pfizer-BioNTech COVID-19 Vaccine, Bivalent; and Registered Trademark Name COMIRNATY®1-5
  • Pfizer is committed to patient safety and ensuring that people have accurate information about the vaccines, including how they are accessed and administered. We are actively monitoring for fraudulent offers of illegitimate vaccines to protect patients from products that might be dangerous and lead to serious and life-threatening harm
    • The vaccines are only administered intramuscularly by a healthcare professional
    • The vaccines are not taken orally and is not available in a capsule or tablet form

  • Authentic vaccines, manufactured by Pfizer Inc., will include the Pfizer and BioNTech names on the label and can be visually verified via this page.
  • Ensure the security of the vaccine vials by limiting access to only authorized personnel. The location they are stored in must be secure and locked when not in use.
    To prevent counterfeits, discard vaccine vials in sharps containers and empty vial cartons as medical waste or deface or safely crush all materials so they cannot be reused. Remember, the vaccines are only available through established medical centers – such as doctor’s offices, pharmacies, outpatient clinics, community vaccination locations, and hospitals. The vaccines can only be administered by licensed healthcare professionals, or other individuals that are approved vaccinators. Individual doses are not for sale.
If you suspect the vaccine you have purchased may be counterfeit, contact us at 1-800-438-1985 or visit https://www.pfizer.com/products/product-contact-information.

To learn more, visit https://www.pfizer.com/counterfeiting/frequently-asked-questions.

Administrative Information

OPEN ALL

CLOSE ALL

What are the Current Procedural Terminology (CPT) codes?8

The CPT code for Pfizer-BioNTech COVID-19 Vaccine, 6 months through 4 years of age, DILUTE BEFORE USE, Maroon Cap is 91308. The administrative code is 0081A for the first dose and 0082A for the second dose.

The CPT code for Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), 6 months through 4 years of age, DILUTE BEFORE USE, Maroon Cap is 91317 for the third dose in the primary series. The administrative code for the third dose is 0173A.

The CPT code for the Pfizer-BioNTech COVID-19 Vaccine (5 through 11 years of age) DILUTE BEFORE USE, Orange Cap presentation is 91307. The administrative code is 0071A for the first dose, 0072A for the second dose, 0073A for the third dose, immunocompromised only.

The CPT code for the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (5 through 11 years of age), DILUTE BEFORE USE, Orange Cap presentation is 91315.

The CPT code for COMIRNATY® (COVID-19 Vaccine, mRNA), 12 years of age and older, DO NOT DILUTE, Gray Cap and Pfizer-BioNTech COVID-19 Vaccine, 12 years of age and older, DO NOT DILUTE, Gray Cap is 91305. The administrative code is 0051A for the first dose, 0052A for the second dose, and 0053A for the third dose.

The CPT code for Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), 12 years of age and older, DO NOT DILUTE, Gray Cap are 91312 (vaccine code) and 0124A (administration code).

New CPT codes are anticipated after the American Medical Association (AMA) publishes them. Please continue to check the AMA site for updated content: https://www.ama-assn.org/find-covid-19-vaccine-codes.

[By clicking the above link, you will be redirected to a website that is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of this site.]

What are the National Drug Codes (NDCs)?1-5

The NDC for a multiple dose vial of Pfizer-BioNTech COVID-19 Vaccine, 6 months through 4 years of age, DILUTE BEFORE USE, Maroon Cap is 59267-0078-1; 10-pack carton code is 59267-0078-4.

The NDC for a multiple dose vial of Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), 6 months through 4 years of age, DILUTE BEFORE USE, Maroon Cap is 59267-0609-1; 10-pack carton code is 59267-0609-2.

The NDC for a 10-pack carton of multiple dose vials of Pfizer-BioNTech COVID-19 Vaccine (5 through 11 years of age) DILUTE BEFORE USE, Orange Cap is 59267-1055-4.

The NDC for a multiple dose vial of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (5 through 11 years of age), DILUTE BEFORE USE, Orange Cap is 59267-0565-1; 10-pack carton code is 59267-0565-2.

The NDC for 10-pack carton of multiple dose vials of COMIRNATY® (COVID-19 Vaccine, mRNA), 12 years of age and older, DO NOT DILUTE, Gray Cap is 0069-2025-10; 25-pack carton code is 0069-2025-25.

The NDC for 10-pack carton of Pfizer-BioNTech COVID-19 Vaccine, 12 years of age and older, DO NOT DILUTE, Gray Cap is 59267-1025-4; 25-pack carton code is 59267-1025-3.

The NDC for a single dose vial of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), 12 years of age and older, DO NOT DILUTE, Gray Cap is 59267-1404-1; 10-pack carton code is 59267-1404-2.

The NDC for a multiple dose vial of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), 12 years of age and older, DO NOT DILUTE, Gray Cap is 59267-0304-1; 10-pack carton code is 59267-0304-2.

Please note updated commercial NDCs will become available at time of transition to commercial market.

Ensuring the Authenticity of Pfizer-BioNTech COVID-19 Vaccine; Pfizer-BioNTech COVID-19 Vaccine, Bivalent; and Registered Trademark Name COMIRNATY®

  • Pfizer is committed to patient safety and ensuring that people have accurate information about the vaccines, including how they are accessed and administered. We are actively monitoring for fraudulent offers of illegitimate vaccines to protect patients from products that might be dangerous and lead to serious and life-threatening harm
    • The vaccines are only administered intramuscularly by a healthcare professional3221,2
    • The vaccines are not taken orally and are not available in a capsule or tablet form3221,2
  • Authentic vaccines, manufactured by Pfizer Inc., will include the Pfizer and BioNTech names on the label and can be visually verified via this page.
  • Ensure the security of the vaccine vials by limiting access to only authorized personnel. The location they are stored in must be secure and locked when not in use.
    To prevent counterfeits, discard vaccine vials in sharps containers and empty vial cartons as medical waste or deface or safely crush all materials so they cannot be reused. Remember, the vaccines are only available through established medical centers – such as doctor’s offices, authorized pharmacies, outpatient clinics, community vaccination locations, and hospitals. The vaccines can only be administered by licensed healthcare professionals, or other individuals that are approved vaccinators, at government-authorized vaccination sites. Individual doses are not for sale6,93,48,126,76,96,75,66,9

If you suspect the vaccine you have purchased may be counterfeit, contact us at 1-800-438-1985 or visit https://www.pfizer.com/products/product-contact-information.

To learn more, visit https://www.pfizer.com/counterfeiting/frequently-asked-questions.


References
  1. Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5). Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers)  (6 months through 4 years of age), DILUTE BEFORE USE, Maroon Cap. Pfizer and BioNTech; December 8, 2022.
  2. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (5 through 11 years of age), DILUTE BEFORE USE, Orange Cap. Pfizer and BioNTech; December 8, 2022.
  3. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers), Bivalent (Original and Omicron BA.4/BA.5), (Booster Dose for 5 through 11 years of age), DILUTE BEFORE USE, Orange Cap. Pfizer and BioNTech; December 8, 2022.
  4. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) (12 years of age and older), DO NOT DILUTE, Gray Cap. Pfizer and BioNTech; December 8, 2022.
  5. Pfizer-BioNTech COVID-19 Vaccine. Emergency Use Authorization Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers), Bivalent (Original and Omicron BA.4/BA.5) (Booster Dose for 12 years of age and older), DO NOT DILUTE, Gray Cap. Pfizer and BioNTech; December 8, 2022.
  6. COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations – October 29, 2020 Version 2.0. Centers for Disease Control and Prevention; 2020.
  7. Data on file. Pfizer Inc. New York, NY.
  8. Centers for Medicare & Medicaid Services. COVID-19 vaccines and monoclonal antibodies. Accessed February 8, 2023. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies
  9. McCurry MC. Secure disposal of vaccine vials and packaging recommendations. US Department of Defense; 2021.

Authorized Use

Important Safety Information

Expand

Collapse

Important Safety Information



Authorized Use

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is authorized for use under an Emergency Use Authorization (EUA) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 6 months of age and older.

This EUA Prescribing Information pertains only to Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), hereafter referred to as Pfizer-BioNTech COVID-19 Vaccine, Bivalent.



Important Safety Information

Do not administer Pfizer-BioNTech COVID-19 Vaccine, Bivalent to individuals with known history of a severe allergic reaction (eg, anaphylaxis) to any component of Pfizer-BioNTech COVID-19 Vaccine or Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Management of Acute Allergic Reactions

Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Monitor vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/managing-anaphylaxis.html).

Myocarditis and Pericarditis

Postmarketing data with authorized or approved monovalent mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following receipt of the second primary series dose or first booster dose, with most booster doses likely administered at least 5 months after completing primary vaccination. For Pfizer-BioNTech COVID-19 Vaccine, the observed risk is higher among adolescent males and adult males under 40 years of age than among females and older males, and the observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, in particular in adolescents. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Limitation of Effectiveness

Pfizer-BioNTech COVID-19 Vaccine, Bivalent may not protect all vaccine recipients.

Adverse Reactions

The safety of a booster dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent is based on:

  • safety data from a clinical study which evaluated a booster dose of Pfizer-BioNTech’s bivalent COVID-19 vaccine (Original and Omicron BA.1), not authorized or approved, hereafter referred to as bivalent vaccine (Original and Omicron BA.1),
  • safety data from clinical trials which evaluated primary and booster vaccination with Pfizer-BioNTech COVID-19 Vaccine, and
  • post marketing safety data with Pfizer-BioNTech COVID-19 Vaccine.

The safety data accrued with the bivalent vaccine (Original and Omicron BA.1) and with Pfizer-BioNTech COVID-19 Vaccine are relevant to Pfizer-BioNTech COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.

The clinical study (30 mcg modRNA) that evaluated a booster dose of the bivalent vaccine (Original and Omicron BA.1) included participants greater than 55 years of age. Adverse reactions following administration of the bivalent vaccine (Original and Omicron BA.1) as a second booster dose included pain at the injection site (58.1%), fatigue (49.2%), headache (33.6%), muscle pain (22.3%), chills (13.0%), joint pain (11.3%), injection site redness (7.0%), injection site swelling (6.6%), fever (5.0%), lymphadenopathy (0.3%), nausea (0.3%), and malaise (0.3%).

In a clinical study (30 mcg modRNA) of participants 18 through 55 years of age, adverse reactions following administration of a first booster dose of Pfizer-BioNTech COVID-19 Vaccine were pain at the injection site (83.0%), fatigue (63.7%), headache (48.4%), muscle pain (39.1%), chills (29.1%), joint pain (25.3%), lymphadenopathy (5.2%), nausea (0.7%), decreased appetite (0.3%), rash (0.3%), and pain in extremity (0.3%). Severe allergic reactions (including anaphylaxis), myocarditis, and pericarditis have been reported following administration of Pfizer‑BioNTech COVID-19 Vaccine.

In a clinical study (10 mcg modRNA) of participants 5 through 11 years of age, adverse reactions following administration of a single booster dose of Pfizer-BioNTech COVID-19 Vaccine were injection site pain (73.9%), fatigue (45.6%), headache (34.0%), muscle pain (18.3%), injection site swelling (16.4%), injection site redness (15.6%), chills (10.5%), fever (6.7%), joint pain (6.7%), diarrhea (4.9%), lymphadenopathy (2.5%), and vomiting (2.4%).

Post Authorization Experience

Severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions (eg, rash, pruritus, urticaria, angioedema), diarrhea, vomiting, pain in extremity (arm), syncope, and dizziness have been reported following administration of Pfizer-BioNTech COVID-19 Vaccine.

Myocarditis and pericarditis have been reported following administration of Pfizer-BioNTech COVID-19 Vaccine.

Additional adverse reactions, some of which may be serious, may become apparent with post authorization use of Pfizer-BioNTech COVID-19 Vaccine, Bivalent.

Before administration, please click to see:

EUA Fact Sheet for Vaccination Providers

EUA Fact Sheet for Recipients and Caregivers


For More Information

Medical Information

Pfizer Customer Service

Call 1-800-879-3477

Medical Information

Medical Information

Visit PfizerMedicalInformation.com or call 1-800-438-1985

Medical Information

Shipment Support
US Trade Customer Service

Call 1-800-666-7248

Phone

Get COVID-19 vaccine-related info texted directly to your mobile device

Enroll in the
BioNTech & Pfizer COVID Connect
text messaging program for US Healthcare Professionals.


vial-img mobile-vial-img

General Product Inquiries

Call 1-877-829-2619

Information Updates

Gray Close Button

Emergency Use Authorization

Emergency uses of Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent have not been approved or licensed by FDA but have been authorized by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) in individuals aged 6 months and older as appropriate. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)  (1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com.

Now Authorized: Effective 03/14/23

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is now authorized for use in individuals 6 months through 4 years of age to provide a single booster dose at least 2 months after completion of primary vaccination with 3 doses of the monovalent Pfizer-BioNTech COVID-19 Vaccine

NOTE: The original monovalent Pfizer-BioNTech COVID-19 Vaccine was previously but is no longer authorized for use as the third dose of the primary series in individuals 6 months through 4 years of age.

Click to view the EUA Fact Sheet for Vaccination Providers, Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) (6 months through 4 years of age), DILUTE BEFORE USE, Maroon Cap

Changes include but are not limited to the following sections:
New Language in Teal and Bold

2.3 Vaccination Schedule
. . .

Booster Dose

The Pfizer-BioNTech COVID-19 Vaccine, Bivalent is authorized for use in individuals 6 months through 4 years of age to provide a single booster dose (0.2 mL) at least 2 months after completion of primary vaccination with 3 doses of the Pfizer-BioNTech COVID-19 Vaccine.

NOTE: The original monovalent Pfizer-BioNTech COVID-19 Vaccine was previously but is no longer authorized for use as the third dose of the primary series in individuals 6 months through 4 years of age.


6 OVERALL SAFETY SUMMARY
. . .


The safety of Pfizer-BioNTech COVID-19 Vaccine, Bivalent for the third dose of the primary series or booster dose in individuals 6 months through 4 years of age is based on:

  • safety data from clinical studies which evaluated a booster dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) in individuals 6 months of age and older,
  • safety data from a clinical study which evaluated a booster dose with Pfizer-BioNTech’s bivalent COVID-19 vaccine (Original and Omicron BA.1), not authorized or approved, hereafter referred to as bivalent vaccine (Original and Omicron BA.1) in individuals greater than 55 years of age,
    • The safety data accrued with the bivalent vaccine (Original and Omicron BA.1) and with the Pfizer-BioNTech COVID-19 Vaccine are relevant to the Pfizer-BioNTech COVID-19 Vaccine, Bivalent because these vaccines are manufactured using the same process.
  • safety data from clinical studies which evaluated primary vaccination with Pfizer-BioNTech COVID-19 Vaccine in individuals 6 months of age and older and
  • safety data from clinical studies which evaluated booster vaccination with Pfizer-BioNTech COVID-19 Vaccine (previously, but no longer, authorized) in individuals 5 years of age and older, and
  • postmarketing safety data with the Pfizer-BioNTech COVID-19 Vaccine and the Pfizer-BioNTech COVID-19 Vaccine, Bivalent

. . .

Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

The Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) is made up of equal parts of modRNA encoding the S-glycoprotein of SARS-CoV-2 Wuhan-Hu1 strain (Original) and modRNA encoding the S-glycoprotein of SARS-CoV-2 Omicron variant lineage BA.4 and BA.5.

In a clinical study C4591048 (Study 6) in participants 6 through 23 months of age who received a booster (fourth dose) of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (3 mcg modRNA), adverse reactions following administration of the vaccine included irritability (18.2%), drowsiness (9.1%), injection site redness (8.3%), decreased appetite (4.5%), fatigue (4.2%), fever (4.2%), pain at the injection site (4.2%), and injection site swelling (4.2%).

In a clinical study C4591048 (Study 6) in participants 2 through 4 years of age who received a booster (fourth dose) of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (3 mcg modRNA), adverse reactions following administration of the vaccine included fatigue (30.6%), pain at the injection site (27.8%), injection site redness (8.3%), diarrhea (5.6%), injection site swelling (2.8%), vomiting (2.8%) headache (2.8%), joint pain (2.8%), and chills (2.8%).

In a clinical study C4591048 (Study 6) in participants 5 through 11 years of age who received a booster (fourth dose) of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (10 mcg modRNA), adverse reactions following administration of the vaccine included pain at the injection site (64.0%), fatigue (40.5%), headache (25.2%), muscle pain (13.5%), joint pain (9.0%), chills (9.0%), injection site redness (7.2%), fever (4.5%), injection site swelling (4.5%), vomiting (3.6%), diarrhea (3.6%), and lymphadenopathy (0.9%).

In a clinical study C4591044 (Study 5) in participants 12 years of age and older who received a booster (fourth dose) of Pfizer-BioNTech COVID-19 Vaccine, Bivalent (30 mcg modRNA), adverse reactions following administration of the vaccine included pain at the injection site (68.5%), fatigue (56.4%), headache (41.4%), muscle pain (25.8%), chills (16.9%), joint pain (13.4%), diarrhea (9.6%), fever (7.3%), injection site swelling (5.4%), injection site redness (4.5%), vomiting (1.9%), and lymphadenopathy (0.3%).

Verify the vials (including labels) prior to preparation and administration to help avoid dosing errors. Check gray cap, orange cap, and maroon cap vial labels to ensure that:

  • For original monovalent vaccine, the name on the vial label states: Pfizer-BioNTech COVID-19 Vaccine
  • For bivalent vaccine, the name on the vial label states: Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5)

Please see the Formulation/Presentation Guide for more details.

Expiry Information

Regardless of storage condition, the maroon cap, orange cap, and gray cap vaccines should not be used after 18 months from the date of manufacture printed on the vials and cartons.

Close
Scroll to continue to site